Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1998-12-28
2001-04-17
Graser, Jennifer (Department: 1641)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S190100, C424S200100, C530S350000, C536S023700, C435S069100, C435S069300, C435S071100
Reexamination Certificate
active
06217884
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the 37-kDa
Streptococcus pneumoniae
surface adhesin A protein. Specifically, the invention relates to an isolated nucleic acid encoding the 37-kDa protein of
Streptococcus pneumoniae,
to unique fragments of the nucleic acid encoding the 37-kDa protein of
Streptococcus pneumoniae,
and to the polypeptides encoded by those nucleic acids. The invention further relates to antibodies to those polypeptides, and to methods of detecting the presence of
Streptococcus pneumoniae,
methods of preventing
Streptococcus pneumoniae
infection, and methods of treating a
Streptococcus pneumoniae
infection.
2. Background Art
Pneumococcal disease continues to be a leading cause of sickness and death in the United States and throughout the world. Both the lack of efficacy of the currently used polysaccharide vaccines in children under 2 years of age and their variable serotype-specific efficacy among vaccinated individuals, have prompted manufacturers to investigate alternative vaccine formulations that do not require the use of multiple capsular polysaccharides. One current approach under consideration is the use of immunogenic species-common proteins as vaccine candidates. These proteins could be used in combination with other immunogenic proteins or as protein carriers in a protein-polysaccharide or oligosaccharide conjugate vaccine. An effective vaccine that included a common protein could eliminate the need for formulations based on multiple capsular polysaccharides (as in the 23-valent polysaccharide vaccine) by offering a broader range of protection against a greater number of serotypes. Additionally, a protein-based vaccine would be T-cell dependent and provide a memory response, resulting in a more efficacious vaccine.
Of the reported pneumococcal proteins, only pneumolysin and the pneumococcal surface protein A (PspA) have been extensively examined for their suitability as vaccine candidates. While both have been shown to be partially protective in mice (Paton et al. 1983. “Effect of immunization with pneumolysin on survival time of mice challenged with
Streptococcus pneumoniae.”
Infect. Immun. 40:548-552 and McDaniel et al. 1991. “PspA, a surface protein of
Streptococcus Pneumoniae,
is capable of eliciting protection against pneumococci of more than one capsular type.” Infect. Immun. 59:222-228), there are disadvantages to their use as vaccine immunogens. Pneumolysin, although well conserved among pneumococci, has been shown to have strong toxic effects in its native state (AlonsoDeVelasco et al. 1995.
“Streptococcus pneumoniae:
Virulence factors, pathogenesis, and vaccines.” Microbiol. Rev. 59:591-603). Recombinant derivatives of reduced toxicity have been produced, and while they show promise in animal protection studies (Alexander et al. 1994. “Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of
Streptococcus pneumoniae.
Infect. Immun. 62:5683-5688) the problem of maintaining maximal immunogenicity and eliminating toxicity to humans is still in question. PspA, on the other hand, is serologically and structurally heterogeneous. (Crain et al. 1990. “Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of
Streptococcus pneumoniae.”
Infect. Immun. 58:3293-3299). Its use in vaccine formulations would require multiple PspA types, thus increasing the complexity of vaccine preparation.
An immunogenic species-common protein has been identified from
Streptococcus pneumoniae.
(Russell et al. 1990. “Monoclonal antibody recognizing a species-specific protein from
Streptococcus pneumoniae.”
J. Clin. Microbiol. 28:2191-2195 and U.S. Pat. No. 5,422,427 in which the 37-kDa protein is referred to as pneumococcal fimbrial protein A). The 37-kDa
S. pneumoniae
protein has been the focus of several studies and has been designated pneumococcal surface adhesin protein A (PsaA). Immunoblot analysis studies using anti-PsaA monoclonal antibody showed that PsaA is common to all 23 pneumococcal vaccine serotypes (Russell et al. 1990). Enzyme-linked-immunosorbent assay studies have indicated that patients with pneumococcal disease show an antibody increase in convalescent-phase serum to PsaA compared with acute-phase serum antibody levels (Tharpe et al. 1995. “Purification and seroreactivity of pneumococcal surface adhesin A (PsaA).” Clin. Diagn. Lab. Immunol. 3:227-229 and Tharpe et al. 1994. “The utility of a recombinant protein in an enzyme immunoassay for antibodies against
Streptococcus pneumoniae.”
abstr. V-2, p. 617. 1994. American Society for Microbiology, Washington, D.C.). Additionally, a limited in vivo protection study showed that antibodies to the 37-kDa protein protect mice from lethal challenge (Talkington et al 1996. “Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA).” Microbial Pathogenesis 21:17-22).
The gene encoding PsaA from
S. pneumoniae
strain R36A (an unencapsulated strain) has been cloned in
Escherichia coli
and sequenced, but this serotype does not contain a 37 kDa protein encoding nucleic acid that is highly conserved among the various serotypes. (Sampson et al. 1994. “Cloning and nucleotide sequence analysis of psaA, the
Streptococcus pneumoniae
gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins.” Infect. Immun. 62:319-324). This particular nucleic acid and polypeptide, therefore, are of limited value for use as diagnostic reagents, in infection prevention, in infection treatment, or in vaccine development.
Sequence conservation is a necessary requirement for a candidate species-common vaccine. At present, there are no studies that have investigated the sequence conservation of the psaA gene among pneumococcal types, specifically among encapsulated pneumococci which cause the vast majority of serious disease. Therefore, a need exists to investigate the conservation of the gene in order to provide a polypeptide which can serve as a vaccine for multiple strains of
Streptococcus pneumoniae.
The present invention fulfills that need by analyzing psaA genes from the 23 serotypes in the 23-valent polysaccharide vaccine and by providing a polypeptide and antibodies to that polypeptide which are conserved among the
S. pnuemoniae
serotypes and which confer protection to
Streptococcus pneumoniae
infection.
SUMMARY OF THE INVENTION
In accordance with the purpose(s) of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to an isolated nucleic acid encoding the 37-kDa protein of
Streptococcus pneumoniae
as set forth in the Sequence Listing as SEQ ID NO:2. The invention also provides unique fragments of at least 10 nucleotides of the nucleic acid set forth in the Sequence Listing as SEQ ID NO:1, which can be used in methods to detect the presence of
Streptococcus pneumoniae
in a sample and as immunogenic vaccines.
The invention further provides a purified polypeptide encoded by the nucleic acid encoding the 37-kDa protein of
Streptococcus pneumoniae
as set forth in the Sequence Listing as SEQ ID NO:1, which can be used as immunogenic vaccines.
In another aspect, the invention provides purified antibodies which bind to the 37-kDa protein of
Streptococcus pneumoniae
or fragments thereof. These antibodies can be used in methods to detect the presence of
Streptococcus pneumoniae
in a sample and in therapeutic and prophylactic methods.
The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
Throughout this application, various publications are referenced. The disclosures of these publi
Ades Edwin W.
Carlone George M.
Russell Harold
Sampson Jacquelyn S.
Tharpe Jean A.
Graser Jennifer
Needle & Rosenberg P.C.
The United States of America as represented by the Department of
LandOfFree
Streptococcus pneumoniae 37-kDa surface adhesin a protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcus pneumoniae 37-kDa surface adhesin a protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcus pneumoniae 37-kDa surface adhesin a protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2437635